These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15714755)

  • 21. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
    Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
    Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 23. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients.
    Taylor JE; Henderson IS; Stewart WK; Belch JJ
    Lancet; 1991 Nov; 338(8779):1361-2. PubMed ID: 1682739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The adverse effects of recombinant human erythropoietin therapy.
    Wong KC; Li PK; Lui SF; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(4):183-206. PubMed ID: 2088088
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects.
    Eschbach JW; Haley NR; Egrie JC; Adamson JW
    Kidney Int; 1992 Aug; 42(2):407-16. PubMed ID: 1405323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of uremic bleeding by hereditary storage pool disease.
    Berty RM; Zeigler ZR; Bruns FJ
    Am J Kidney Dis; 1992 Apr; 19(4):326-30. PubMed ID: 1562020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombocytopathy and blood complications in uremia].
    Hörl WH
    Wien Klin Wochenschr; 2006 Apr; 118(5-6):134-50. PubMed ID: 16773479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelets and platelet function in patients with chronic uremia on maintenance hemodialysis.
    Jørgensen KA; Ingeberg S
    Nephron; 1979; 23(5):233-6. PubMed ID: 481658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 30. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet hyperactivity and risk of recurrent thrombosis.
    Harrison P; Keeling D
    J Thromb Haemost; 2006 Dec; 4(12):2544-6. PubMed ID: 17026648
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of bleeding in dialysis patients.
    Galbusera M; Remuzzi G; Boccardo P
    Semin Dial; 2009; 22(3):279-86. PubMed ID: 19573008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of recombinant erythropoietin on sexual function in hemodialysis patients.
    Schaefer RM; Kokot F; Heidland A
    Contrib Nephrol; 1989; 76():273-81; discussion 281-2. PubMed ID: 2684527
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients.
    Akizawa T; Kinugasa E; Kitaoka T; Koshikawa S
    Nephron; 1991; 58(4):400-6. PubMed ID: 1922603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia.
    Nomura S; Hamamoto K; Kawakatsu T; Kido H; Yamaguchi K; Fukuroi T; Suzuki M; Yanabu M; Shouzu A; Nishikawa M
    Nephron; 1994; 68(4):442-8. PubMed ID: 7870229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients.
    Malyszko J; Mazerska M; Malyszko J; Pawlak K; Azzadin A; Mysliwiec M; Buczko W
    Int J Clin Lab Res; 1993; 23(1):42-4. PubMed ID: 8477092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of erythropoietin on tissue factor and tissue factor pathway inhibitor in uremic hemodialysis patients].
    Bronowicz A; Perkowski H; Pawlak K
    Pol Arch Med Wewn; 2004 Jul; 112(1):787-96. PubMed ID: 15526838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 40. Tackling the diabetic platelet: is high clopidogrel dosing the answer?
    Angiolillo DJ
    J Thromb Haemost; 2006 Dec; 4(12):2563-5. PubMed ID: 16968328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.